Sort
50,496 grants matching “lung cancer”
Elucidating the Role of cGAS-STING in Lung Tissue Repair and Remodeling
$578,492Karen M Ridge · Northwestern University At Chicago · R01 · FY2025 · HL
Engage: A Randomized Controlled Trial Testing the Efficacy of a Telehealth-Delivered Psychosocial Intervention to Decrease Symptom Interference in Patients with Advanced Cancer
$578,467Joseph Giles Winger · Duke University · R01 · FY2024 · CA
Enhancing Chemoradiation Efficacy through Unbiased Drug Discovery Approaches
$578,444Steven Hsesheng Lin · University Of Tx Md Anderson Can Ctr · U01 · FY2019 · CA
Towards Translation of MU-CN29: New Therapeutic Nanoparticle for Drug-Resistant NSCLC
$578,421Raghuraman Kannan · University Of Missouri-Columbia · R01 · FY2023 · CA
Objective decision support environment for clinical trials
$578,313Bradley J. Erickson · Mayo Clinic Rochester · U01 · FY2012 · CA
Impact of State Cannabis Laws on Cancer Pain Management and Outcomes: A mixed-methods study
$578,284Devon Check · Duke University · R37 · FY2024 · CA
COHORT MANAGEMENT
$578,205Patricia L Blount · Fred Hutchinson Cancer Research Center · P01 · FY2014 · CA
Faith Moves Mountains: A CBPR Appalachian Wellness & Cancer Prevention Program
$578,187Nancy E Schoenberg · University Of Kentucky · R24 · FY2009 · MD
Descriptive Studies and Record Linkage
$578,176Meredith Shiels · Division Of Cancer Epidemiology And Genetics · ZIA · FY2024 · CA
Molecular features impacting drug resistance in atypical EGFR exon 18 and exon 20 mutant non-small cell lung cancers and the development of novel mutant-selective inhibitors
$578,099John V. Heymach · University Of Tx Md Anderson Can Ctr · R01 · FY2021 · CA
Molecular features impacting drug resistance in atypical EGFR exon 18 and exon 20 mutant non-small cell lung cancers and the development of novel mutant-selective inhibitors
$578,099John V. Heymach · University Of Tx Md Anderson Can Ctr · R01 · FY2020 · CA
Immunotherapeutic responses to neoantigens in head and neck cancer
$578,036Ravindra Uppaluri · Dana-Farber Cancer Inst · R01 · FY2020 · DE
Immunotherapeutic responses to neoantigens in head and neck cancer
$578,036Ravindra Uppaluri · Dana-Farber Cancer Inst · R01 · FY2021 · DE
Immunotherapeutic responses to neoantigens in head and neck cancer
$578,036Ravindra Uppaluri · Dana-Farber Cancer Inst · R01 · FY2019 · DE
Addressing racial disparities in lung cancer screening
$578,029Melinda Aldrich · Vanderbilt University Medical Center · R01 · FY2022 · CA
Biomarkers of Response to Immuno-chemotherapy & oliGometastatic Hypofractionated radioTherapy (BRIGHT) for Lung Cancer: Synergy of PET/CT Imaging and Peripheral Blood Assays
$577,989Stephen R. Bowen · University Of Washington · R01 · FY2024 · CA
A new imaging approach to radiotherapy planning for lung cancer
$577,910Rahim R Rizi · University Of Pennsylvania · R01 · FY2018 · CA
NEXT GENERATION SEQUENCING ADD-ON-PHARMACOGENOMICS RESEARCH NETWROK (PGRN)
$577,848Elaine R Mardis · Washington University · U01 · FY2011 · GM
Biomarkers of toxic response to low nicotine cigarette smoke
$577,837Ian Alexander Blair · University Of Pennsylvania · R01 · FY2009 · CA
Smoking and Cancer-Related Health Disparities among Sexual and Gender Minority Adults
$577,803Philip T Veliz · University Of Michigan At Ann Arbor · R01 · FY2024 · CA
Adrenergic control of circadian rhythms in CD8 T cells responding to influenza
$577,768John David Farrar · Ut Southwestern Medical Center · R01 · FY2023 · AI
Dose-distribution radiomics to predict morbidity risk in radiotherapy
$577,764Joseph O Deasy · Sloan-Kettering Inst Can Research · R01 · FY2017 · CA
Project 2: Identifying Metabolic vulnerabilities and targets in cancers with mutations in hamartoma genes
$577,690David J. Kwiatkowski · Brigham And Women'S Hospital · P01 · FY2019 · CA
Discovery of Small Molecule Ligands for PHD1 Reader Domain of Histone Demethylase KDM5A
$577,690Danica Galonic Fujimori · University Of California, San Francisco · R01 · FY2021 · CA
Restoring Salivary Gland Function by Reducing Nucleotide-induced Inflammation
$577,684Gary Andrew Weisman · University Of Missouri-Columbia · R01 · FY2016 · DE